ask why

Latest research

Every new paper in 280 characters, with how strong the evidence is and what readers question about it. Free to read.

Dermatology · Br J Dermatol · 2026-09-18

In 1505 adults with moderate-to-severe plaque psoriasis in two phase III trials, oral icotrokinra gave durable skin clearance to week 52: about 70–75% reached IGA 0/1 or PASI 90 and about 50% IGA 0 or PASI 100 during weeks 24–52, with no safety signals.

RCTn = 1,505
Stein Gold et al. Durability of response to icotrokinra in adults with moderate-to-severe plaque psoriasis: 1-year results from the phase III, placebo- and active comparator-controlled ICONIC-ADVANCE 1 and ICONIC-ADVANCE 2 trials
Dermatology · Br J Dermatol · 2026-09-18

In 453 adults with moderate-to-severe plaque psoriasis responding to ustekinumab, repeated switching to biosimilar ABP 654 met pharmacokinetic similarity versus continued ustekinumab (AUCtau ratio 0.93, Cmax 0.95); efficacy, antidrug antibodies and adverse events were similar.

RCTn = 453
Blauvelt et al. Repeated switching between biosimilar ABP 654 and reference ustekinumab in patients with moderate-to-severe plaque psoriasis: a randomized double-blinded clinical trial to support interchangeability

Sign in to react

Enter your email and we send a 6-digit code and a link. No password.

Your name and role

These appear beside any methods concern you post and on your profile page.